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As the prevalence of hypercholesterolemia is increasing in low- and middle-income coun-
tries (LMICs), detailed evidence is urgently needed to guide the response of health systems
to this epidemic. This study sought to quantify unmet need for hypercholesterolemia care
among adults in 35 LMICs.
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Methods and findings
We pooled individual-level data from 129,040 respondents aged 15 years and older from 35
nationally representative surveys conducted between 2009 and 2018. Hypercholesterol-
emia care was quantified using cascade of care analyses in the pooled sample and by
region, country income group, and country. Hypercholesterolemia was defined as (i) total
cholesterol (TC)�240 mg/dL or self-reported lipid-lowering medication use and, alterna-
tively, as (ii) low-density lipoprotein cholesterol (LDL-C)�160 mg/dL or self-reported lipid-
lowering medication use. Stages of the care cascade for hypercholesterolemia were defined
as follows: screened (prior to the survey), aware of diagnosis, treated (lifestyle advice and/
or medication), and controlled (TC <200 mg/dL or LDL-C <130 mg/dL). We further estimated
how age, sex, education, body mass index (BMI), current smoking, having diabetes, and
having hypertension are associated with cascade progression using modified Poisson
regression models with survey fixed effects.
High TC prevalence was 7.1% (95% CI: 6.8% to 7.4%), and high LDL-C prevalence was
7.5% (95% CI: 7.1% to 7.9%). The cascade analysis showed that 43% (95% CI: 40% to
45%) of study participants with high TC and 47% (95% CI: 44% to 50%) with high LDL-C
ever had their cholesterol measured prior to the survey. About 31% (95% CI: 29% to 33%)
and 36% (95% CI: 33% to 38%) were aware of their diagnosis; 29% (95% CI: 28% to 31%)
and 33% (95% CI: 31% to 36%) were treated; 7% (95% CI: 6% to 9%) and 19% (95% CI:
18% to 21%) were controlled. We found substantial heterogeneity in cascade performance
across countries and higher performances in upper-middle-income countries and the East-
ern Mediterranean, Europe, and Americas. Lipid screening was significantly associated with
older age, female sex, higher education, higher BMI, comorbid diagnosis of diabetes, and
comorbid diagnosis of hypertension. Awareness of diagnosis was significantly associated
with older age, higher BMI, comorbid diagnosis of diabetes, and comorbid diagnosis of
hypertension. Lastly, treatment of hypercholesterolemia was significantly associated with
comorbid hypertension and diabetes, and control of lipid measures with comorbid diabetes.
The main limitations of this study are a potential recall bias in self-reported information on
received health services as well as diminished comparability due to varying survey years
and varying lipid guideline application across country and clinical settings.
Conclusions
Cascade performance was poor across all stages, indicating large unmet need for hyper-
cholesterolemia care in this sample of LMICs—calling for greater policy and research atten-
tion toward this cardiovascular disease (CVD) risk factor and highlighting opportunities for
improved prevention of CVD.
Author summary
Why was this study done?
• The prevalence of hypercholesterolemia is increasing in low- and middle-income coun-
tries (LMICs).
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countries. Microdata can be downloaded (upon




country surveys included in this analysis that are
publicly available through the STEPS Microdata
repository (https://extranet.who.int/ncdsmicrodata/
index.php/catalog/STEPS) are: Algeria 2016-2017,
Azerbaijan 2017, Belarus 2015, Benin 2014, Bhutan
2014, Botswana 2014, Eswatini 2014, Guyana
2016�, Iraq 2015, Kiribati 2015, Kyrgyzstan 2013,
Lebanon 2017, Moldova 2013, Mongolia 2013,
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2015, Sudan 2016, Tajikistan 2016-2017, Timor-
Leste 2014, Tuvalu 2015, Vietnam 2015, Zambia
2017. For the remaining countries, please contact
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St. Vincent and the Grenadines, which are member
countries of the Caribbean Public Health Agency
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2016 STEPS survey also became publicly available
on the STEPS Microdata repository.
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• Evidence on how well health systems address this rising hypercholesterolemia burden is
limited. Nationally representative studies analyzing care at the individual level across a
larger number of LMICs are largely missing.
What did the researchers do and find?
• We analyzed access to hypercholesterolemia care using pooled data from 35 nation-
ally representative, individual-level surveys from LMICs.
• We found a prevalence of high total cholesterol (TC) of 7.1% (95% CI: 6.8% to 7.4%)
and a high low-density lipoprotein cholesterol (LDL-C) prevalence of 7.5% (95% CI:
7.1% to 7.9%) in this set of countries.
• Using a cascade of care approach, we found that 43% (95% CI: 40% to 45%) of individ-
uals with high TC and 47% (95% CI: 44% to 50%) with high LDL-C ever had their cho-
lesterol measured prior to the survey. About 31% (95% CI: 29% to 33%) and 36% (95%
CI: 33% to 38%) were aware of their diagnosis; 29% (95% CI: 28% to 31%) and 33%
(95% CI: 31% to 36%) were treated; 7% (95% CI: 6% to 9%) and 19% (95% CI: 18% to
21%) were controlled.
• Using modified Poisson regression models, we found that access to care was signifi-
cantly associated with a range of sociodemographic characteristics, such as high edu-
cation and old age, as well as with the presentation of other cardiovascular disease
(CVD) risk factors, such as comorbid diabetes or hypertension and a high body
mass index.
What do these findings mean?
• We found large unmet need for hypercholesterolemia care in this sample of LMICs.
• This calls for greater policy and research attention toward this CVD risk factor.
• High-performing countries, such as Sri Lanka, Costa Rica, Iran, and Morocco, may
highlight policy opportunities for improved prevention of CVD.
• The main limitations of this study are a potential recall bias in self-reported information
on received health services as well as diminished comparability due to varying survey
years and varying lipid guideline application across country and clinical settings.
Introduction
Cardiovascular disease (CVD) is already the leading cause of death in low- and middle-
income-countries (LMICs) and is projected to increase rapidly in the coming decades [1,2].
Hypercholesterolemia—defined as abnormal levels of blood lipids, such as high fasting total
cholesterol (TC)—is the second leading physiological risk factor for CVD after high blood
pressure [3,4]. High cholesterol was estimated to cause 3.5 million deaths and 81.4 million
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cholesterol; WHO PEN, WHO Package of Essential
Noncommunicable Disease Interventions for
Primary Health Care in Low-Resource Settings;
WHO, World Health Organization.
disability-adjusted life years (DALYs) in LMICs in 2019 [3]. Importantly, the disease burden
caused by hypercholesterolemia is eminently preventable with lifestyle modification and low-
cost, off-patent medications [4–7]. The fact that a high burden persists suggests that many
health systems in LMICs are still ill-equipped to address this important condition.
Despite the importance of rigorous evidence to guide health policy and improve healthcare
delivery, the current empirical evidence remains weak and offers only a limited understanding
of the state of care for hypercholesterolemia in LMICs [8,9]. Research is mainly confined to
single countries, often based on a subnational level with a focus on specific subpopulations, or
to single healthcare indicators, such as access to essential medicines [8,10–13]. To our knowl-
edge, nationally representative studies analyzing broader health system performance at the
individual level across a larger number of LMICs have been altogether absent.
Our analysis aims to address this dearth of evidence by identifying the unmet need for
hypercholesterolemia care using a pooled dataset of nationally representative, population-
based surveys that includes 129,040 individuals from 35 LMICs. We assess the unmet need for
care by applying the cascade of care approach, a quantitative depiction of the screening, diag-
nosis, treatment, and control stages within the care system of the affected population groups.
This methodology has been widely used to monitor care responses to the HIV epidemic and is
increasingly applied to examine the management of chronic diseases, such as diabetes or
hypertension [14–17]. We estimate the cascade of care for individuals, separately for high TC
and high low-density lipoprotein cholesterol (LDL-C), (i) in a pooled sample across all 35
LMICs and (ii) disaggregated at the World Health Organization’s (WHO) epidemiological
subregion [18], World Bank country income classification [19], and country level. We then
estimate the associations between individual-level characteristics and cascade completion—
yielding insights into the overall unmet need for care as well as into potentially underserved
subpopulations in this group of LMICs.
Methods
Ethics
This study received a determination of “not human subjects research” by the institutional
review board of the Harvard T.H. Chan School of Public Health.
Data sources
The included datasets were obtained through a systematic request approach. We first targeted
surveys following the WHO’s Stepwise Approach to Surveillance of Noncommunicable Dis-
ease (NCD) Risk Factors (STEPS). We identified responsible contacts for each survey via the
WHO STEPS website, expert contacts, a web search, and the WHO NCD Microdata repository
[20]. Inclusion criteria were as follows: surveys had to be conducted during or after 2008; had
to come from an upper-middle, lower-middle, or low-income country per World Bank defini-
tion during the survey year [19]; be nationally representative with a response rate of over 50%;
have data available at the individual level; include biomarkers for hypercholesterolemia (TC or
LDL-C); and include questions that assess the access to health services for diagnosis, preventive
counseling, and treatment of hypercholesterolemia. Whenever STEPS surveys were not avail-
able, we searched for complementing data meeting the inclusion criteria. A detailed protocol
and outcome of the search process is provided in S1 Text.
This process yielded 32 STEPS surveys from 2010 to 2018 to be included in our analysis:
Algeria, Azerbaijan, Bangladesh, Belarus, Benin, Bhutan, Botswana, Burkina Faso, Costa Rica,
Ecuador, Eswatini, Guyana, Iran, Iraq, Kiribati, Kyrgyzstan, Lebanon, Moldova, Mongolia,
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Morocco, Myanmar, Solomon Islands, Sri Lanka, St. Vincent and the Grenadines, Sudan,
Tajikistan, Timor-Leste, Tokelau, Tonga, Tuvalu, Vietnam, and Zambia.
Supplementary to these, we added the 2009/10 National Health Survey from Chile, the 2013
National Survey of Noncommunicable Diseases from Seychelles, and the 2017 HYBRID Sur-
vey from the Marshall Islands. All surveys used multistage cluster random sampling to select
participants. Details on the sampling strategies can be found in S2 Text.
Cascade construction
The cascade-of-care methodology first requires the identification of individuals with hyper-
cholesterolemia to serve as the overall sample. Our definition of hypercholesterolemia is con-
tingent upon a collected biomarker sample and self-reported medication use. We used 2 lipid
biomarkers to establish a set of hypercholesterolemia definitions—TC and LDL-C. TC is sig-
nificantly and positively associated with ischemic heart disease mortality as well as other CVDs
and is the most commonly measured lipid biomarker in the LMIC literature [4,21]. LDL-C is
the primary target for cholesterol-lowering therapy according to the Adults Treatment Panel
III (ATP III) guidelines of the National Cholesterol Education Program and therefore holds
particular relevance for the analysis of unmet need for care [4,22]. The biomarker cutoffs for
classifying hypercholesterolemia are based on the ATP III guidelines, which are frequently
used in the literature [23–26]. The ATP III provides 3 classifications of TC and 5 classifications
of LDL. The 3 TC classifications are as follows: (i) TC <200 mg/dL is classified as “desirable”;
(ii) 200� TC� 239 is classified as “borderline high”; and (iii) TC�240 is classified as “high”.
The 5 LDL classifications are as follows: (i) LDL-C <100 is classified as “optimal”; (ii)
100� LDL-C� 129 is classified as “near or above optimal”; (iii) 130� LDL-C� 159 is classi-
fied as “borderline high”; (iv) 160� LDL-C� 189 is classified as “high”; and (v) LDL-C�129
is classified as “very high” [4]. We defined hypercholesterolemia as “high” and “very high”
lipid values. We opted for this classification for 2 reasons. First, “high” TC and LDL-C values
have been shown to be associated with an increased lifetime risk of coronary heart disease jus-
tifying clinical therapies and necessitating care [4]. Second, treatment guidelines are usually
based on CVD risk scores rather than on lipid measures alone and often vary across countries
[4,22]. In order to not evaluate health systems by care standards that are in fact unapplied, we
chose to be conservative in our definition of hypercholesterolemia. Thus, we defined hyper-
cholesterolemia based on respondents with (i) a TC measurement of 240 mg/dL or higher or
who were taking lipid-lowering medication and, alternatively, (ii) an LDL-C measurement of
160 mg/dL or higher or taking lipid-lowering medication. However, in supplemental analyses,
we redefine hypercholesterolemia to further include “borderline high” values as well as apply a
definition based on the American College of Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines (AHA/ACC) (AHA/ACC uses an LDL-C cutoff of 70
mg/dL as a threshold for statin therapy in adults 40 to 75 years of age with diabetes or with a
10-year atheroslerotic CVD risk of over 7.5%. In our definition, we classify everyone with an
LDL-C measurement of 70 mg/dL or higher as having hypercholesterolemia) (see S1A–S1C
Fig).
Bangladesh, Chile, Costa Rica, Guyana, Iran, Iraq, and Lebanon measured lipid biomarkers
via blood samples sent to a laboratory. Belarus, Benin, Bhutan, Burkina Faso, Ecuador, Eswa-
tini, Kiribati, Moldova, Morocco, Solomon Islands, Sri Lanka, St. Vincent and the Grenadines,
Sudan, Timor-Leste, Tonga, Vietnam, and Zambia used the CardioCheck PA point-of-care
(POC) device. Seychelles used the Konelab 30i, Mongolia the Prima Home Test, Myanmar the
SD Lipido Care Analyzer, Tokelau the Accutrend GC, and Tuvalu the Accutrend Plus (see
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S3 Text). For the remaining 6 countries, we could not identify whether biomarkers were mea-
sured via a laboratory or a POC machine.
In Algeria, Bangladesh, Burkina Faso, Chile, Costa Rica, Iran, Iraq, Lebanon, Mongolia,
Morocco, Myanmar, Seychelles, and St. Vincent and the Grenadines, both TC and LDL-C rec-
ords were collected, while the remaining countries measured only TC. We took TC records
directly from the survey and derived LDL-C from TC, triglycerides, and HDL cholesterol rec-
ords using the Friedewald equation [27]. Individuals without a biomarker record were
excluded from the analysis (S4 Text). A sensitivity analysis that includes individuals with no
biomarker measurement, for whom hypercholesterolemia is defined purely based on the self-
reported medication status, can be found in S1D Fig. We further excluded observations with
TC records above 300 mg/dL because, even though physiologically very high TC values may
occur, POC devices are not always well equipped to reliably measure these (S4 Text) [28,29].
Supplementary analyses including TC values above 300 mg/dL can be found in S1E Fig.
In a next step, the cascade-of-care analysis requires the measurement of the sample respon-
dents’ met need for hypercholesterolemia care prior to the survey. For this, we defined the fol-
lowing 4 cascade stages expressing each step in the care continuum: (1) ever received a
cholesterol measurement (“Lipids Measured”); (2) ever been told by a healthcare professional
about one’s hypercholesterolemia diagnosis (“Aware of Diagnosis”); (3) received lifestyle
advice or currently taking medication for high cholesterol (“Advice or Medication”); and (4)
has lipid measure in controlled ranges (“Controlled Disease”). Our definition of the last cas-
cade stage was again based on biomarker measurements. We recognize that there usually are
no clinical target ranges for cholesterol alone, and, thus, we chose to define “controlled” lipid
ranges based on the ATP III guidelines’ definition of “desirable”, “optimal”, and “near opti-
mal” values, as was done in related literature [30–32]. Hence, according to our definition, an
individual had controlled lipid values whenever TC was lower than 200 mg/dL and LDL-C was
lower than 130 mg/dL [4]. Supplementary cascade analyses based on a definition that further
considers “borderline high” values (�200 and<240 mg/dL TC;�130 and<160 mg/dL
LDL-C) as “controlled” lipid values can be found in S1F Fig.
The cascade stages “Lipids Measured”, “Aware of Diagnosis”, and “Advice or Medication”
were measured with self-reported interview data. Across surveys, the question phrasing of
these cascade measures was almost identical as is shown in S4 Text. “Lipids Measured” refers
to lipid measurements that had taken place prior to the survey. For “Advice or Medication”
(3), advice refers to lifestyle advice about physical activity, body weight, fruit and vegetable
intake, special diets, reduction of fat, or tobacco consumption. Medication refers to any oral
treatment for high cholesterol.
Statistical analysis
In the cascade-of-care analysis, we calculated the share of respondents that reach each conse-
cutive cascade stage over the denominator of all individuals with hypercholesterolemia defined
either as high TC or as high LDL-C. We estimated the cascades of care for the pooled sample
as well as at the WHO epidemiological subregion, World Bank country income classification,
and country level for both hypercholesterolemia definitions. In addition to this, we carried out
a pooled cascade analysis on a restricted sample of individuals with hypercholesterolemia for
whom cholesterol screening is recommended according to international guidelines. This
allows an examination of health system performance in relation to adherence to approved care
guidelines. We derived the screening recommendation guidelines from the WHO Package of
Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-
Resource Settings [33]. The PEN protocol specifies that individuals exhibiting any one of the
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following risk factors should be included in the routine management of CVD risk and undergo
cholesterol screening: age>40 years; current smoking; waist circumference�90 cm in males
or�100 cm in females; having diabetes; or having hypertension [33].
We adjusted all cascade estimations for survey sampling designs using the “svy set” com-
mand with subpopulation specifications in Stata 16.1 (StataCorp, College Station, Texas,
United States), used R’s ggplot2 package for the disaggregated cascade graphics, and R’s gee-
pack package as well as Stata 16.1 for regression estimations [34].
In addition to the cascade analyses, we estimated individual-level correlates of cascade pro-
gression. We regressed the proportion of respondents with high TC or high LDL-C that
reached each cascade stage on age, sex, education, smoking, body mass index (BMI), diabetes,
and hypertension status. In this, we adjusted our standard errors for clustering at the primary
sampling unit level and included survey fixed effects (for mathematical equations, see S5 Text).
The regression analyses were not weighted [35]. We used a modified Poisson regression model
yielding risk ratios (RRs) as our main specification and supplemented our analysis with addi-
tional univariable and multivariable models and an analysis of deviance in S2 Table [36].
Covariate measurement
Age, smoking status, and education were self-reported. Sex was recorded as observed. We cal-
culated respondents’ BMI from height and weight measurements that were taken alongside
waist circumference measurements. The hypertension status was derived from blood pressure
readings and the diabetes status from collected blood glucose measurements. Hypertension
was defined as a systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at
least 90 mm Hg, or reported use of medication for hypertension. Diabetes was defined as fast-
ing plasma glucose of at least 7.0 mmol/l (126 mg/dl), random plasma glucose of at least 11.1
mmol/l (200 mg/dl), HbA1c of at least 6.5%, or reporting to be taking medication for diabetes.
More details on the definition and measurement of these comorbidities are provided elsewhere
[15,16].
STROBE guidelines
This study is reported as per the Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) guideline (see S6 Text).
Results
Sample characteristics
Our sample included 129,040 individuals from 35 LMICs over a 9-year period (2009 to 2018).
Details on country-specific sample characteristics can be found in S1A Table. Sociodemo-
graphic characteristics of the respondents are displayed in Table 1 stratified by biomarkers.
We found that 7.1% (95% CI: 6.8% to 7.4%) of individuals had high TC and 7.5% (95% CI:
7.1% to 7.9%) had high LDL-C (also see S1C Table). The mean age of the overall sample was
around 40 to 41 years (SD: 14 years), whereas the mean age in those with either form of hyper-
cholesterolemia was around 49 years (SD: 13 to 14 years). Secondary schooling or higher edu-
cation was completed by 41% of those with high TC and 31% of those with high LDL-C.
Around 59% to 61% of those with hypercholesterolemia were overweight or obese, and
approximately 16% to 17% were current smokers. Comorbid diabetes occurred in 23% to 24%
of those with hypercholesterolemia and hypertension in 49% to 52%. Around 87% to 89% of
those with hypercholesterolemia exhibited at least 1 associated risk factor, indicating that cho-
lesterol screening was recommended for them. Sample characteristics of respondents who had
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Table 1. Sociodemographic sample characteristics by hypercholesterolemia definition.
TC Sample� LDL-C Sample��



















128,998 7 10,737 100 58,332 7 6,315 100
Female 128,996 51 10,732 51 58,330 52 6,314 59
Age(mean) 128,998 40 10,733 49 58,332 41 6,315 49
15–24 y/o 12,290 15 194 3 3,184 12 88 3
25–34 y/o 29,555 26 820 13 12,882 26 512 14
35–44 y/o 30,445 23 1,713 19 14,278 24 1,024 19
45–54 y/o 26,964 18 2,967 28 12,824 19 1,689 27
55–64 y/o 20,757 13 3,328 26 9,728 13 1,842 24




25,566 21 1,906 24 12,719 26 1,456 29
Less than secondary
school
39,406 34 3,470 35 20,784 39 2,376 39
Secondary completed
or higher
62,086 45 5,064 41 23,767 35 2,292 31
BMI
Normal 53,969 52 2,750 38 22,596 48 1,584 36
Underweight 8,323 10 231 3 3,538 9 113 3
Overweight 36,438 25 3,790 37 18,591 28 2,385 38
Obese 28,024 13 3,715 22 12,465 15 2,068 23
Smoking# 128,329 20 10,699 16 57,974 20 6,292 17
Diabetic 121,887 8 10,062 24 57,288 9 6,190 23
Hypertensive 127,755 27 10,650 52 57,766 27 6,265 49
Screening
recommended§
128,998 68 10,733 89 58,332 70 6,315 87
Total Number of
Observation
128,998 10,737 58,332 6,315
�Includes respondents from all 32 countries with a valid TC measurement (see S4 Text); columns “Sample With High TC” restricted to respondents with high TC
(defined by exceeding ATP III guideline cutoffs, i.e., TC�6.21 mmol/L, or respondent taking lipid medication).
��Includes respondents from Algeria, Bangladesh, Burkina Faso, Chile, Costa Rica, Iran, Iraq, Lebanon, Mongolia, Morocco, Myanmar, Seychelles, and St. Vincent and
the Grenadines with a valid LDL-C measurement (see S4 Text); columns “Sample With High LDL-C” restricted to respondents with high LDL-C (defined by exceeding
ATP III guideline cutoffs, i.e., LDL-C�4.14 mmol/L, or respondent taking lipid medication).
���Refers to high TC in columns 1–4 and high LDL-C in columns 5–8. See S1C Table for 95% confidence intervals.
†Unweighted.
‡Values account for sampling design with survey weights rescaled by the survey’s sample size such that all countries contribute to estimates according to their population
size.
#Respondents that are currently smoking or were smoking within past 12 months are classified as smoking (as per WHO PEN disease interventions for primary
healthcare in low-resource settings (WHO PEN) Protocol 1).
§According to the PEN protocol, screening is recommended whenever the respondent exhibits at least one of the following risk factors: age >40; smoking; diabetic;
hypertensive; waist circumference > = 90 in males; waist circumference > = 100 in females.
ATP III, Adults Treatment Panel III; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; WHO PEN, World Health Organization
package of essential noncommunicable disease interventions for primary healthcare in low-resource settings.
https://doi.org/10.1371/journal.pmed.1003841.t001
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TC and LDL-C measures in normal ranges and who reported not taking lipid-lowering medi-
cation can be found in S1B Table.
Pooled cascades of care
The cascades of care for the pooled country sample are displayed in Fig 1A and 1B. Only 43%
(95% CI: 40% to 45%) of those with high TC and 47% (95% CI: 44% to 50%) with high LDL-C
had had their blood lipids measured prior to the survey. In those with high TC (Fig 1A), 31%
(95% CI: 29% to 33%) were diagnosed, and 29% (95% CI: 28% to 31%) were treated. Only 7%
(95% CI: 6% to 9%) of individuals with high TC achieved control. Of those with high LDL-C
(Fig 1B), less than half were diagnosed (36%, 95% CI: 33% to 38%), 33% (95% CI: 31% to 36%)
were treated, and 19% (95% CI: 18% to 21%) achieved control.
Fig 1C and 1D display cascade results for individuals meeting PEN criteria for lipid screen-
ing. Cascade performance was found to be similar compared to the previous analyses: Only
45% of respondents with high TC and for whom screening was recommended according to
PEN guidelines had undergone a cholesterol measurement.
Furthermore, S1 Fig shows a range of supplementary analyses. The cascade of care based on
a definition that also classifies “borderline high” TC as hypercholesterolemia shows by design
a substantially poorer performance. Similarly, cascade performance is markedly worse when
basing the hypercholesterolemia definition on cutoffs from the AHA/ACC guidelines. The cas-
cades of care for high TC restricted to the countries that collected both TC and LDL-C records
mirrored those for high LDL-C care. The cascade of care restricted to respondents aged 40 or
older mirrors the cascade results for individuals meeting PEN criteria for lipid screening.
Finally, neither estimates including TC records over 300 mg/dL nor those using a more inclu-
sive definition of controlled lipid values show substantial differences in cascade performance
in comparison to the cascade of care presented in Fig 1.
Disaggregated cascade of care
Fig 2 displays the cascades of care disaggregated by WHO epidemiological subregion, World
Bank country income class, and country (for results in table format, see S2 Table). The Ameri-
cas and Eastern Mediterranean and Europe regions achieved comparatively high cascade of
care levels: 66% (95% CI: 61% to 71%) of individuals with hypercholesterolemia in the Ameri-
cas and 52% (95% CI: 49% to 55%) of those in the Eastern Mediterranean and Europe regions
have ever had their cholesterol measured. Examining the same cascade stage for Africa and
Southeast Asia and Western Pacific, we found shares of 29% (95% CI: 21% to 40%) and 34%
(95% CI: 30% to 38%), respectively. As the cascade progresses, all regions converge to under
15% at the control stage. We found substantial heterogeneity across countries. Iran displayed
the best cascade performance—89% (95% CI: 88% to 91%) of individuals with hypercholester-
olemia have had their cholesterol measured prior to the survey, and around 57% (95% CI: 54%
to 60%) were still retained at the control stage. Other high-performing countries included
Costa Rica, Belarus, Ecuador, Morocco, and Sri Lanka (see S2D Table). Benin, Bhutan, Eswa-
tini, Kiribati, Myanmar, Solomon Islands, and Zambia exhibited the greatest unmet need for
care. In each case, fewer than 20% of those with hypercholesterolemia ever had their choles-
terol measured leaving the consecutive cascade stages at very low levels. Achieved levels of con-
trol were low almost in all of the 32 countries, with less than 10% in 26 countries. Next to Iran,
only Morocco achieved comparably high levels of control, where 49% (95% CI: 41% to 58%) of
those with high TC reached the last cascade stage. Cascade performance was found to be con-
sistently higher in upper-middle-income countries.
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Individual-level characteristics and cascade progression
In estimating the association between individual-level characteristics and cascade progression,
we found a significant age gradient for reaching the first and second cascade stages—for
instance, over-65-year-olds were 2.09 times (95% CI: 1.67 to 2.60; p-value:<0.001) more likely
to have had their cholesterol measured in comparison to the youngest age group (see Table 2).
The age gradient disappeared in the treatment cascade stage and was found to be insignificant
in the control stage. We further observed that women were significantly more likely to have
Fig 1. Cascades of care by biomarker. Bars represent point estimates; numeric form can be viewed above bars. Whiskers represent 95% confidence intervals;
numeric form of upper and lower bounds can be viewed above and below whiskers. On top, the absolute percentage point drops of each cascade step are shown
on the left-hand side and the relative percentage drop on the right-hand side. Note: All calculations incorporate PSUs and strata to account for the different
survey designs of included countries, as well as use sampling weights rescaled such that all countries contribute equally. Percentage and percentage point drops
are calculated with unrounded point estimates. Hypercholesterolemia refers to all respondents that are classified as having high TC, i.e., TC�240 mg/dL, or
high LDL-C, i.e., LDL-C�160 mg/dL, or a self-reported medication status. Lipids Measured refers to the percentage share of all respondents with
hypercholesterolemia (classified based on respective biomarker) that have ever had their lipid status measured prior to the survey as per self-reported
information. Accordingly, Aware of Diagnosis refers to the percentage share of all participants with hypercholesterolemia that have (self-reportedly) ever been
diagnosed by a medical professional with hypercholesterolemia, whereas Advice or Medication refers to those that have received medication or lifestyle advice
for their disease. Controlled Disease considers those respondents that have TC and LDL-C values within the range considered normal by ATP III guidelines.
Panel (a) only considers TC and the self-reported medication status in the classification of having hypercholesterolemia. Panel (b) only considers LDL-C and
the self-reported medication status in the classification of having hypercholesterolemia. Included are all countries that measured LDL-C, namely, Algeria,
Bangladesh, Burkina Faso, Chile, Costa Rica, Iran, Iraq, Lebanon, Mongolia, Morocco, Myanmar, Seychelles, and St. Vincent and the Grenadines. Panel (c)
again considers TC and the self-reported medication status in the classification of hypercholesterolemia. It further restricts the sample to those respondents
with hypercholesterolemia for which screening is recommended based on the exhibition of at least one of the following risk factors: age>40; current smoking;
having diabetes; having hypertension; waist circumference�90 in males and�100 in females. Panel (d) again considers LDL-C and the self-reported
medication status in the classification of having hypercholesterolemia. It further restricts the sample again to those respondents with hypercholesterolemia for
which screening is recommended (as in Panel c). Included are all countries that measured LDL-C, namely, Algeria, Bangladesh, Burkina Faso, Chile, Costa
Rica, Iran, Iraq, Lebanon, Mongolia, Morocco, Myanmar, Seychelles, and St. Vincent and the Grenadines. ATP III, Adults Treatment Panel III; LDL-C, low-
density lipoprotein cholesterol; PSU, primary sampling unit; TC, total cholesterol.
https://doi.org/10.1371/journal.pmed.1003841.g001
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been screened than men (RR: 1.06; 95% CI: 1.03 to 1.10; p-value:<0.001) but less likely reach
the control stage (RR: 0.92; 95% CI: 0.86 to 0.98; p-value: 0.007). Individuals with secondary
education or higher were also significantly more likely to have been screened compared to
Fig 2. Cascade of care for high TC by WHO epidemiological subregion and World Bank GDP income
classification. Bars represent pooled region point estimates. Whiskers represent pooled region 95% confidence
intervals. Dots represent country point estimates; dots are color coded by GDP income classification; highest and
lowest performing country of each region is indicated by country abbreviation. Note: Several countries have point
estimates of zero at the control stage, in which case they were abbreviated by the letters A�, B�, and C�. A�: Benin,
Botswana, Burkina Faso, Eswatini, and Zambia. B�: Azerbaijan, Belarus, Kyrgyzstan, Moldova, Sudan, and Tajikistan.
C�: Bhutan, Kiribati, Marshall Islands, Solomon Islands, Sri Lanka, Timor-Leste, Tokelau, Tonga, Tuvalu, and
Vietnam. D�: Ecuador and Guyana. The country abbreviations follow the ISO 3166-1Alpha-3 codes: BEN, Benin;
BGD, Bangladesh; CRI, Costa Rica; DZA, Algeria; GUY, Guyana; IRN, Iran; KIR, Kiribati; LKA, Sri Lanka; SLB,
Solomon Islands; TJK, Tajikistan; VCT, St. Vincent and the Grenadines; ZMB, Zambia. Other abbreviations: S.E. Asia,
Southeast Asia; TC, total cholesterol. For more details, see note.
https://doi.org/10.1371/journal.pmed.1003841.g002
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those who did not complete primary schooling (RR: 1.25; 95% CI: 1.20 to 1.30; p-value:
<0.001) but showed no significant association with reaching other cascade stages. Being a
smoker showed only weakly significant, negative associations with having undergone a lipid
screening (RR: 0.96; 95% CI: 0.92 to 1.00; p-value: 0.07) and treatment (RR: 0.97; 95% CI: 0.94
to 1.00; p-value: 0.03). Individuals who were overweight or obese were significantly (p-value:
<0.001) more likely to have been screened and diagnosed in comparison to individuals with a
normal BMI. Moreover, having diabetes or hypertension were found to have RRs significantly
(p-value: <0.001) greater than 1 for reaching the lipid measurement, diagnosis, or treatment
stage. Diabetes further had a significant and positive association with having had a lipid mea-
sure in controlled ranges.
Table 2. Correlates of cascade progression.
Measured Diagnosed Treated Controlled
RR p RR p RR p RR p
Age
15–24 years REF REF REF REF
25–34 years 1.17 [0.93,1.48] 0.18 1.12 [0.85,1.49] 0.41 0.91 [0.82,1.01] 0.07 1.19 [0.62,2.29] 0.61
35–44 years 1.63 [1.30,2.03] <0.001 1.31 [1.01,1.71] 0.04 0.95 [0.87,1.03] 0.22 1.34 [0.72,2.49] 0.35
45–54 years 1.86 [1.49,2.32] <0.001 1.41 [1.09,1.83] 0.009 0.96 [0.89,1.04] 0.33 1.39 [0.75,2.57] 0.30
55–64 years 2.04 [1.64,2.55] <0.001 1.46 [1.13,1.89] 0.004 0.97 [0.90,1.06] 0.54 1.43 [0.78,2.65] 0.25
65 or older 2.09 [1.67,2.60] <0.001 1.43 [1.10,1.85] 0.007 0.99 [0.91,1.07] 0.73 1.61 [0.87,2.98] 0.13
Sex
Male REF REF REF REF
Female 1.06 [1.03,1.10] <0.001 1.01 [0.98,1.04] 0.53 0.99 [0.97,1.01] 0.22 0.92 [0.86,0.98] 0.007
Education
Less than primary school REF REF REF REF
Less than secondary school 1.06 [1.02,1.10] 0.004 1.02 [0.98,1.05] 0.35 1.01 [0.99,1.02] 0.41 1.03 [0.96,1.11] 0.45
Secondary school completed or higher 1.25 [1.20,1.30] <0.001 1.01 [0.97,1.05] 0.52 1.00 [0.98,1.02] 0.97 1.01 [0.93,1.10] 0.74
Smoking
Past or Never REF REF REF REF
Current 0.96 [0.92,1.00] 0.07 0.96 [0.92,1.01] 0.13 0.97 [0.94,1.00] 0.03 1.02 [0.93,1.12] 0.71
BMI
Normal REF REF REF REF
Underweight 0.74 [0.62,0.88] <0.001 1.01 [0.87,1.17] 0.89 0.98 [0.91,1.06] 0.65 1.16 [0.90,1.50] 0.26
Overweight 1.08 [1.04,1.12] <0.001 1.08 [1.04,1.12] <0.001 0.99 [0.97,1.01] 0.20 1.03 [0.96,1.12] 0.39
Obese 1.15 [1.11,1.20] <0.001 1.08 [1.04,1.12] <0.001 0.99 [0.97,1.01] 0.45 1.01 [0.93,1.09] 0.86
Diabetes 1.19 [1.15,1.22] <0.001 1.10 [1.07,1.13] <0.001 1.02 [1.01,1.04] <0.001 1.21 [1.14,1.28] <0.001
Hypertension 1.15 [1.12,1.19] <0.001 1.09 [1.05,1.13] <0.001 1.04 [1.02,1.06] <0.001 1.04 [0.98,1.11] 0.18
N 10,575 6,073 4,601 4,283
Multivariable modified Poisson regression models with robust error structure, clustering at PSU, including binary country variables (survey-level “fixed effects”), and
“Lipids Measured,” “Aware of Diagnosis,” “Advice or Medication,” and “Controlled Disease” as dependent variables. Each cascade stage estimation is conditioned on
completion of prior cascade stages. The coefficients indicate RRs. 95% confidence intervals in brackets. The regression samples do not include Tokelau, due to
information on education not being available, nor Tonga, due to unavailable blood glucose measurements. Survey fixed effect estimates can be viewed in S1K Fig.
Respondents that are currently smoking or were smoking within past 12 months are classified as current smokers (as per WHO PEN disease interventions for primary
healthcare in low-resource settings (WHO PEN) Protocol 1).
BMI, body mass index; PSU, primary sampling unit; REF, reference; RR, risk ratio; WHO PEN, WHO PEN, World Health Organization Package of Essential
Noncommunicable Disease Interventions for primary healthcare in low-resource settings.
https://doi.org/10.1371/journal.pmed.1003841.t002
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Discussion
In a pooled sample of 129,040 individuals from 35 LMICs, we found that less than 1 out of
every 3 respondents with hypercholesterolemia had been treated and less than 1 in 5 had
achieved control. By using nationally representative data that combine individual-level bio-
markers with self-reported health service utilization, our study shows that cascade perfor-
mance, while poor overall, is characterized by large declines at the screening and control stage
in particular. To our knowledge, this is a first application of the cascade of care methodology
to such an extensive evaluation of the unmet need for hypercholesterolemia care, yielding
novel insights into the shortcomings of health services in this geographically diverse group of
countries.
The results of this study have several important policy implications for health system
strengthening. We found that screening for hypercholesterolemia constitutes a major barrier
to meeting care needs, as this stage was consistently found to have the largest or second largest
amount of loss along the cascade of care. In the US and Europe, where cholesterol screening
rates varied in ranges comparable to our study, screening appeared to be influenced by struc-
tural health system inequities and was found to be lower in disadvantaged groups—such as
racial minorities or those with low education [37–39]. Our results show that in this set of
LMICs education was also positively associated with screening. We estimated that individuals
with secondary education or higher had a 25% higher likelihood of being screened relative to
individuals with less than primary education. Potential reasons for this could be that additional
schooling results in better health literacy and greater awareness of CVD risk or—as a proxy for
wealth and social status—better access to the health system. In addition to sociodemographic
characteristics, we also found the presence of other CVD risk factors, such as age, high BMI, or
comorbid diabetes or hypertension, to be associated with screening. This suggests that health
systems are—in accordance with WHO guidance—targeting high-risk individuals for screen-
ing. However, while many individuals with hypercholesterolemia who were included in this
study presented with at least 1 other CVD risk factor, cascade performance did not improve
overall when examining this group only. This suggests that a large proportion of high-risk
individuals were still left out of screening efforts. In cases where this relates to a lack of labora-
tory infrastructure and equipment as well as accessibility and affordability of care, POC
machines may have the potential to increase screening rates among all population groups [40].
We also found large losses at the stage of diagnosis, as approximately only one-third of all
individuals with hypercholesterolemia was found to be aware of their high cholesterol. Our
results further showed that age, high BMI, having diabetes, and having hypertension were sig-
nificantly associated with being aware of one’s high cholesterol level. This suggests that health-
care workers may appropriately prioritize those at greatest risk of CVD across the cascade, not
only at the screening stage as described above. In the case of diabetes, this significant effect per-
sisted through the final “control” stage of the cascade of care. This is an encouraging finding
given the markedly worse CVD outcomes of patients with diabetes in comparison to those
without [41]. Our results are in line with the current evidence base, as studies undertaken in
several high- and upper-middle-income countries also found age and high CVD risk to be
associated with greater awareness of having hypercholesterolemia [8,26,42]. Furthermore,
while we did not find sex to be significantly associated with having received a hypercholesterol-
emia diagnosis, it is worth noting that prior studies have reported significant, albeit inconsis-
tent patterns of sex differences [8,25,30].
The smallest loss in the care cascade—both in absolute and relative terms—occurred
between the diagnosis and treatment stages. This is consistent with lifestyle advice essentially
being cost free and previous evidence that found declining costs of cholesterol-lowering
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medications in LMICs [8]. Nonetheless, a loss in care at this stage suggests that obstacles to
treatment delivery persist. Here, previous evidence points toward a lack of access to and
affordability of medicines, as well as the variation in treatment guidelines that influence clini-
cal decisions [8,10,11,43]. On the international scale, this is reflected in the WHO’s List of
Essential Medicines, which currently includes only simvastatin for mixed hyperlipidemia.
However, given the low treatment rates, expanding this list to include other statins, such as
atorvastatin, pravastatin, fluvastatin, or lovastatin—which are currently only listed as therapeu-
tic equivalents to simvastatin—could be one potential approach to increase their uptake [44].
Finally, a drop of 42% to 75% from all that received treatment for hypercholesterolemia to
those that achieved control marked the largest relative loss in the care cascade. Both in the
pooled analysis and at the country level, control rates were found to be low, ranging from vir-
tually zero to 27% in all but 2 countries—Iran (57%) and Morocco (49%). This finding should
be interpreted with the understanding that common treat-to-target ranges for lipids are not
universally applied and are often combined with coronary heart disease risk levels, which
could not be included in this study due to a lack of data availability [45]. Nonetheless, this find-
ing is also reflected in other studies, where control rates in China, Thailand, and Jordan also
ranged between 10% and 25% [8,30]. Such low control rates may reflect both insufficient treat-
ment options available to providers, for instance, due to a lack of access to affordable medica-
tion as described above or due to poor treatment adherence by respondents. While
improvements in medication availability may improve the former, a large literature base is cur-
rently forming around policy interventions such as mobile health or peer and community edu-
cation to improve uptake and adherence to lipid-lowering therapy [46,47].
Generally, we found that the Americas, the Eastern Mediterranean, and European regions
achieved higher cascade performance than Africa, Southeast Asia, and the Western Pacific
regions. We further showed that upper-middle-income countries were consistently better at
retaining individuals throughout the cascade than lower-middle income or low-income coun-
tries. This pattern may reflect that hypercholesterolemia care requires a level of attention that
countries with low health system capacity may not be able or willing to achieve yet. Because
hypercholesterolemia care is embedded in a framework of comprehensive CVD care, it is
shaped by several clinical complexities of calculating risk scores, still comparably expensive
screening and treatment options, and an international context that focuses on policies to target
each of the cardiometabolic risk factors individually, for instance, through initiatives such as
the WHO Global Diabetes Compact [10,11,33,48].
Within these patterns, we still found very large heterogeneity at the country level across all
cascade stages, which is mirrored in the literature [8,25,26,30]. It is particularly noteworthy
that Sri Lanka and Morocco were among the highest-performing countries—despite their
lower-middle-income status. Sri Lanka has been shown to be highly engaged in fighting
NCDs. They have a national NCD agenda, a high share of primary healthcare facilities that
offer CVD risk management, cardiac rehabilitation programs, as well as policies targeting
tobacco, alcohol and salt reductions, and NCDs generally [49–51]. Sri Lanka was also found to
have the highest number of full-time equivalent professional staff in an NCD unit within the
Ministry of Health in comparison to 6 other Asian countries [49]. The high performance of
Morocco, on the other hand, was not mirrored in prior, yet limited literature. These studies
have shown that while Morocco is already undergoing the epidemiological transition, the
awareness of ischemic heart disease and CVD risk remained low in the population [52–54].
Hence, future research may yield valuable insights into the strengths and weaknesses of the
Moroccan NCD care system. After Morocco and Sri Lanka, Costa Rica and Iran stood out as
particularly high-performing, upper-middle-income countries. Notably, Costa Rica performed
similarly well in corresponding analyses of the cascades of care for diabetes and hypertension,
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which also further discuss potential reasons for its high performance [15,16]. In the cascade
analysis for Iran, the high rates of controlled lipid values stood out in particular—which could
be due to increasing statin prescriptions and food industry improvements and further speaks
to Iran’s high capacity for CVD control as well as its leading commitment in the Eastern Medi-
terranean region to fighting NCDs [52,55].
This study had several limitations. First, several measures may be subject to measurement
biases. For one, our data on health services received were self-reported and thus may be sub-
jected to a recall bias. For instance, individuals that were taking medication could have been
more likely to remember ever being screened for hypercholesterolemia, affecting the absolute
probability of reaching each cascade stage. Similarly, recalling the provision of low-touch treat-
ment interventions, such as having received lifestyle advice, may be difficult for respondents.
In addition, our definition of hypercholesterolemia was based on biomarkers that, in some
countries, were measured with POC devices. While these may be less accurate than lab-based
testing, studies have shown that they can be reliably used for lipid screening [29,56–58]. A
study by Ferreira and colleagues (2015) found a 94.6% to 97.7% agreement between the Cardi-
oCheck PA—which is used by the majority of countries—and the laboratory when sorting
lipid records into the ATP III lipid classifications used in our analysis [58]. Moreover, our dis-
aggregated cascade analysis should be considered with the following caveats in mind. First, the
comparability between countries is, to some extent, limited, as the time span of 9 years across
surveys potentially introduced period effects into our analysis. While a cascade analysis by
year showed no observable time trend (see S1L Fig), this must be viewed in light of the fact
that the estimates are based on a small number of surveys per year and that they are likely
heavily enmeshed with country effects. In addition, some country-level estimates have very
small sample sizes due to low prevalence rates and are thus shown only for the purpose of com-
pletion. Relatedly, in our cascade regression analysis, we note that as we conditioned each cas-
cade stage estimation on completion of prior cascade stages, increasing losses in sample size
reduced the statistical power to detect significant associations—potentially explaining our
findings. Finally, we chose to define hypercholesterolemia and achieving control based on the
ATP III guidelines due to their frequent use in the literature. However, these are relatively con-
servative in comparison to some national guidelines, as is apparent when examining the
markedly lower cascade performance when applying AHA/ACC guidelines (see S1C Fig). The
comparability of countries is generally limited by a lack of universally used guidelines, as dif-
ferent guidelines are applied across countries and clinical settings and may even include geo-
graphical parameters, as is the case in the European Society of Cardiology (ESC) and
European Atherosclerosis Society (EAS) guidelines [59,60]. Despite this, such a comparison
still offers important insights into national and global care gaps and can be used for identifying
effective policy as well as serve as markers of progress in tackling the burden of
hypercholesterolemia.
Conclusions
We found low levels of access to hypercholesterolemia care in this group of LMICs, with espe-
cially large levels of unmet screening and control needs across all countries. Further work is
required to understand the underlying causes for this underperformance. A closer examina-
tion of the better performing countries in our study—such as Sri Lanka, Costa Rica, Iran, and
Morocco—could yield important policy lessons, especially as the lipid cascade offers a poten-
tially important tracer of unmet need for chronic disease care. Given its increasing relevance
as one of the major, yet eminently preventable CVD risk factors, hypercholesterolemia
deserves more attention both from a health services and a research perspective, globally.
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